• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Oligonucleotide Therapeutics and Delivery Conference 2020
16 - 17 September 2020, London, UK. Oligonucleotide therapeutics - the emerging medicine class - are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules.
Source: World Pharma News - April 22, 2020 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference
Dateline City: WHITEHOUSE STATION, N.J. Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the company’s anti-PD-1 immunotherapy; expects to complete application in first half of 2014. Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant. Evaluates the role of Merck’s Animal Health and Consumer Care businesses in the company’s strategy for long-term value creation;...
Source: Merck.com - Corporate News - January 13, 2014 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news